85666-17-7

85666-17-7 structure
85666-17-7 structure
  • Name: Furegrelate sodium
  • Chemical Name: furegrelate sodium
  • CAS Number: 85666-17-7
  • Molecular Formula: C15H10NNaO3
  • Molecular Weight: 275.235
  • Catalog: Research Areas Cardiovascular Disease
  • Create Date: 2017-09-10 23:20:57
  • Modify Date: 2026-06-30 12:48:28
  • Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].

Name furegrelate sodium
Synonyms Sodium 5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate
Fureelate Sodium (U-63557A)
Sodium 5-(3-pyridinylmethyl)-2-benzofurancboxylate
sodium styrene sulphonate
p-styrenesulfonic acid sodium salt
sodium styrene-4-sulphonate
Sodium 5-(3-pyridinylmethyl)-1-benzofuran-2-carboxylate
furealate sodium
5-(3-Pyridinylmethyl)benzofurancboxylic acid sodium-potassium salt
sodium 4-styrenesulfonate
FUREELATE SODIUM
SODIUM FUREELATE
Sodium p-Styrenesulfonate
4-Vinylbenzenesulfonic acid sodium salt
FUREELATE SODIUM SALT
sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-cboxylate
5-(3-PYRIDINYLMETHYL)-2-BENZOFURANCBOXYLIC ACID, SODIUM SALT
sodium styrene sulfonate
Styrene-4-sulfonic acid sodium salt
5-(3'-Pyridinylmethyl)benzofuran-2-cboxylate sodium
5-(3-Pyridinylmethyl)-2-benzofurancarboxylic Acid Sodium Salt
2-Benzofurancboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt
U-63557A
Fureelate sodium, 10 mM in DMSO
teries,hypertension,available,Fureelate,inhibit,orally,antiplatelet,platelet,terial,human,stenosed,Inhibitor,pulmony,Fureelate sodium,corony
2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-, sodium salt (1:1)
5-[3,PYRIDINYLMETHYL]BENZO-FURAN-CBOXYLIC ACID SODIUM SALT
5-(3-Pyridylmethyl)benzofuran-2-cboxylic acid sodium salt
C15H11NO3.Na
Sodium 4-vinylbenzenesulfonate
Description Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].
Related Catalog
In Vivo Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery[1]. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1]. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2]. Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme[2]. Animal Model: Mongrel dogs (19-30 kg)[1] Dosage: 1-5 mg/kg Administration: Oral (via a gastric tube) Result: Prevented blockage of the coronary artery.
References

[1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42.

[2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200.

Boiling Point 458.7ºC at 760 mmHg
Molecular Formula C15H10NNaO3
Molecular Weight 275.235
Flash Point 231.2ºC
Exact Mass 275.055847
PSA 66.16000
LogP 1.78210
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.